#United States #Chicago #Belay Diagnostics #CSF Liquid Biopsy #Palantir Technology

Belay Diagnostics Triumphs at Palantir Buildcamp

In the landscape of medical diagnostics, Belay Diagnostics has distinguished itself once more by winning the Palantir Buildcamp competition for the second consecutive year. Specializing in cerebrospinal fluid (CSF) liquid biopsy tests for diagnosing cancers of the central nervous system (CNS), Belay's innovation has set a high standard in molecular diagnostics.

The Buildcamp Challenge

Held in September at Palantir's New York City office, the invitation-only Buildcamp required teams to devise functional solutions using Palantir's extensive software capabilities. A four-member team from Belay Diagnostics crafted a sophisticated interactive molecular case review prototype. This novel application merges comprehensive patient medical histories with results from Belay’s liquid biopsy tests, all organized on a single, interactive timeline. The goal? To empower neuro-oncologists and other specialists to collaboratively analyze complex cases effectively.

Belay's prototype exemplifies its dedication to transforming the diagnostic process by gathering critical clinical and molecular insights that enhance patient management strategies.

Innovations from the Past

This latest victory follows Belay's success in the previous year’s Buildcamp, where their application aimed at automating insurance appeals emerged victorious. The previous tool enabled users to juxtapose payer policies with individual patient medical histories, thus simplifying a typically convoluted process. Both applications were built utilizing Belay's proprietary platform within the Palantir Foundry, showcasing the company’s capabilities in data integration across various sectors such as clinical, laboratory, and business operations.

The Future of Molecular Diagnostics

A noteworthy aspect of Belay Diagnostics' operations is its commitment to integrating AI into its workflows. This commitment is integral not only to the development of cutting-edge applications but also to the optimization of their CSF liquid biopsy testing processes. Belay provides deep molecular insights essential for diagnosing and managing both primary and metastatic CNS cancers, achieving this without requiring invasive tissue biopsies.

In addition to their innovative applications, Belay recently attained SOC 2 attestation after a thorough review of their information security practices. This attestation highlights the company’s robust investment in safeguarding sensitive patient information and building the necessary infrastructure to support its future growth.

As Belay Diagnostics continues to expand, CEO Brian Coe emphasized the importance of innovation in their journey: "Winning two years in a row speaks to the ingenuity of our team and their ability to leverage the power of the Palantir platform to deliver critical capabilities to the patients and physicians we serve," he stated. Coe further indicated that as the company grows, they will focus on creating tools that enhance clinical trial efficiencies and refine revenue cycle management, which are already in operational use at Belay.

Commitment to Patients and Physicians

Belay Diagnostics operates out of Chicago, and is dedicated to providing essential insights for both patients and the medical professionals involved in their care. The company utilizes technology licensed from Johns Hopkins University, reinforced by over a decade of rigorous research, to offer three proprietary CSF liquid biopsy tests: Belay Summit™ 2.0, Belay Ascent™, and Belay Vantage™. These tests facilitate the detection and management of CNS malignancies effectively, delivering comprehensive molecular insights following a standard lumbar puncture within a turnaround time of 6-8 days – no tissue required.

For more information on Belay Diagnostics and their pioneering work in molecular diagnostics, visit belaydiagnostics.com.